Better tools. Better news.
Sunday, November 22, 2026 · UTC
Finance

Trump expands drug pricing agenda with nine more pharmaceutical company deals

President Trump announced nine additional drugmakers have joined 17 others in deals to cap U.S. drug prices at international levels.

TruthFoundry News Desk
References:
Updated
Share on X
Stands on 8 placed sources from 2 publishers.
As of 2026-09-02 02:46 UTC. Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs. [1] Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more. [2] The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program. [3] Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals. [4] The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles. [5] UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals. [6] A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks. [7] The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business. [8]
Proof8 sources · 2 publishers
What this stands on
  1. President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs. · STAT
  2. Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more. · Investing.com
  3. The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program. · Investing.com
  4. Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals. · STAT
  5. The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles. · STAT
  6. UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals. · STAT
  7. A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks. · Investing.com
  8. The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business. · Investing.com
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · 8 sources · v 002The worldThe recordThe writingThe filing

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Wednesday, September 2, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.
Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.
Integrity
Content hash (SHA-256)3cd92a6c09f18d2697f91842e65666b339b6a500af0eba8ff3af4d91b02f5cd1
Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed
Receiptthis revision predates receipt-keeping; the filed row lives on the record
Machine readablethe full proof, JSON
Verify

A signature proves who filed this and that it has not changed since. It never makes a claim true.